2023
Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, A Phase III Randomized Controlled Trial Program
Wunderlich G, Blahova Z, Hake S, Ikezawa S, Marder S, Falkai P, Krystal J. Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, A Phase III Randomized Controlled Trial Program. CNS Spectrums 2023, 28: 229-229. DOI: 10.1017/s1092852923001530.Peer-Reviewed Original ResearchCognitive impairmentEfficacy endpointVirtual Reality Functional Capacity Assessment ToolCognitive symptomsPlacebo-controlled parallel-group trialKey secondary efficacy endpointsN-methyl-D-aspartate receptorsSafety extension studyPrimary efficacy endpointSecondary efficacy endpointsParallel-group trialPhase II trialPoor functional outcomeComposite T-scoreMulti-center studyPhase III programRole of glutamateLong-term safetyScale total scoreDemonstration of efficacyGlycine transporter 1Industry-sponsored studiesCapacity assessment toolII trialTolerability data
2020
Systematic Review of Benzodiazepines for Anxiety Disorders in Late Life
Gupta A, Bhattacharya G, Farheen SA, Funaro M, Balasubramaniam M, Young J, Tampi DJ, Tampi RR. Systematic Review of Benzodiazepines for Anxiety Disorders in Late Life. Annals Of Clinical Psychiatry 2020, 32: 114-127. PMID: 32343283, DOI: 10.1177/104012372003200214.Peer-Reviewed Educational MaterialsConceptsAnxiety disordersSystematic reviewOlder adultsTolerability of benzodiazepinesCochrane Central RegisterMild adverse effectsLater lifeEnglish-language articlesTreatment of anxietyLong-term useWeb of ScienceTolerability dataCentral RegisterControlled TrialsCochrane DatabaseOvid EmbaseLong-term benefitsOvid MEDLINEInclusion criteriaEligible articlesBenzodiazepinesDecreased anxietyStudy periodAdverse effectsTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply